54802-12-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(2-cyanophenoxy)acetamide is used as an intermediate for the synthesis of various pharmaceuticals and agrochemicals. Its unique chemical structure allows it to be a key component in the development of new drugs and other therapeutic agents.
Used in Research and Development:
2-(2-cyanophenoxy)acetamide is used as a subject of research and development in the pharmaceutical industry due to its potential pharmacological and biological activities. Scientists are interested in exploring its properties and applications to create new and innovative treatments.
Used in Organic Synthesis:
2-(2-cyanophenoxy)acetamide is used as a building block in the synthesis of other complex organic molecules. Its versatile chemical structure makes it a valuable component in the creation of a wide range of organic compounds for various applications.

Upstream product

• 611-20-1 salicylonitrile 
• 79-07-2 Chloroacetamide 
• 683-57-8 bromo-acetic acid amide 

Downstream Products

• 1315325-71-3 (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(4-fluorophenylamino)-2-(2-(4-isopropoxyphenyl)benzofuro[3,2-d]pyrimidin-4-yloxy)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide 
• 1315325-52-0 (2R,6S,13aS,14aR,16aS,Z)-N-(cyclo-propylsulfonyl)-6-(4,5-dimethylthiazol-2-ylamino)-5,16-dioxo-2-(2-(4-(trifluoromethyl-)phenyl)benzofuro[3,2-d]pyrimidin-4-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide 
• 1315326-96-5 (2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-5,16-dioxo-6-thioureido-2-(2-(4-(trifluoromethyl)phenyl)benzofuro[3,2-d]pyrimidin-4-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide 
• 1315326-95-4 (2R,6S,13aS,14aR,16aS,Z)-6-amino-N-(cyclopropylsulfonyl)-5,16-dioxo-2-(2-(4-(trifluoromethyl)phenyl)-benzofuro[3,2-d]pyrimidin-4-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrol-e[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide hydrochloride 
• 1195976-53-4 C₄₃H₄₇F₃N₆O₉S 
• 1315326-82-9 (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-(2-(4-isopropoxy-phenyl)benzofuro[3,2-d]pyrimidin-4-yloxy)pyrrolidine-2-carboxamide hydrochloride salt 
• 1315326-79-4 C₃₈H₄₃N₅O₉S 
• 1315324-53-8 methyl 2-((2S)-1-((2S,4R)-2-((2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl-carbamoyl)-4-(2-(4-(trifluoromethyl)phenyl)benzofuro[3,2-d]pyrimidin-4-yloxy-)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-ylamino)thiazole-4-carboxylate 
• 1315326-73-8 (2S,4R)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-(2-(4-(trifluoromethyl)phenyl)benzofuro[3,2-d]pyrimidin-4-yloxy)pyrrolidine-2-carboxamide hydrochloride 
• 1315326-72-7 C₄₂H₄₇F₃N₆O₉S 
• 1315326-71-6 (2S,4R)-N-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-(2-(4-(trifluoromethyl)phenyl)benzofuro[3,2-d]pyrimidin-4-yloxy)pyrrolidine-2-carboxamide hydrochloride 
• 1315326-70-5 C₃₆H₃₆F₃N₅O₈S 
• 1315326-80-7 (2S,4R)-N-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-(2-(4-isopropoxyphenyl)benzofuro[3,2-d]pyrimidin-4-yloxy)pyrrolidine-2-carboxamide hydrochloride 
• 1315324-63-0 (2S,4R)-N-((1R,2S)-1-(cyclopropylsulfonylcarbamoyl-)-2-vinylcyclopropyl)-1-((S)-3,3-dimethyl-2-(4-methylthiazol-2-ylamino)butanoyl)-4-(2-(4-isopropoxyphenyl)benzofuro[3,2-d]pyrimidin-4-yloxy)pyrrolidine-2-carboxamide 

Relevant academic research and scientific papers

Discovery of XL413, a potent and selective CDC7 inhibitor

CDC7 is a serine/threonine kinase that has been shown to be required for the initiation and maintenance of DNA replication. Up-regulation of CDC7 is detected in multiple tumor cell lines, with inhibition of CDC7 resulting in cell cycle arrest. In this paper, we disclose the discovery of a potent and selective CDC7 inhibitor, XL413 (14), which was advanced into Phase 1 clinical trials. Starting from advanced lead 3, described in a preceding communication, we optimized the CDC7 potency and selectivity to demonstrate in vitro CDC7 dependent cell cycle arrest and in vivo tumor growth inhibition in a Colo-205 xenograft model.

The design, synthesis, and biological evaluation of PIM kinase inhibitors

A series of substituted benzofuropyrimidinones with pan-PIM activities and excellent selectivity against a panel of diverse kinases is described. Initial exploration identified aryl benzofuropyrimidinones that were potent, but had cell permeability limitation. Using X-ray crystal structures of the bound PIM-1 complexes with 3, 5m, and 6d, we were able to guide the SAR and identify the alkyl benzofuropyrimidinone (6l) with good PIM potencies, permeability, and oral exposure.

HCV PROTEASE INHIBITORS

This invention relates to compounds of Formula (I), (II), or (III) shown in the specification. These compounds can be used to treat hepatitis C virus infection.

Syntheses of 3-acetoacetylaminobenzo[b]furan derivatives having cysteinyl leukotriene 2 receptor antagonistic activity

Novel 3-acetoacetylaminobenzo[b]furan derivatives having a modified triene system at the 3-position were synthesized starting with 3-aminobenzo[b]furans. The enol isomers, 3-[(3-hydroxybul-2-enonyl)amino]benzo[b]furans (1), of the 3-acetoacetylaminobenzo[b]furans were obtained as stable isomers owing to formation of a hydrogen bonding between the enol hydroxyl group and the amidocarbonyl group. The planarity of the C-2 substituent through the C-3 side chain suggested the existence of a modified conjugational triene system in the enol compound. Cysteinyl leukotriene 1 and 2 receptor antagonistic activities for these compounds were evaluated. 2-(4-Cyanobenzoyl or ethoxycarbonyl)-3-[(2-cyano-3-hydroxybut-2-enonyl)amino]benzo[e]furans (15g, 15o, 15u) were moderately active.